Insmed Inc (INSM)vsSepterna, Inc. Common Stock (SEPN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SEPN
Septerna, Inc. Common Stock
$24.21
+3.28%
HEALTHCARE · Cap: $1.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1220% more annual revenue ($606.42M vs $45.95M). INSM leads profitability with a -2.1% profit margin vs -106.4%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SEPN
Avoid33
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 11276.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -12.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SEPN
The strongest argument for SEPN centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 11276.0% demonstrates continued momentum.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SEPN
The primary concerns for SEPN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SEPN is a hypergrowth play — different risk/reward profiles.
SEPN is growing revenue faster at 11276.0% — sustainability is the question.
SEPN generates stronger free cash flow (-15M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Septerna, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Septerna, Inc. is an innovative biotechnology company at the forefront of developing transformative therapeutics via selective protein modulation. With a commitment to addressing unmet medical needs across diverse disease areas, Septerna leverages proprietary platforms and deep scientific acumen to advance a robust pipeline of next-generation drug candidates. The company's strategic focus on research and development, coupled with its potential for significant clinical impact, positions it as a compelling opportunity for institutional investors seeking exposure in the dynamic biopharmaceutical sector.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?